Achim was appointed CEO of InfanDx in January 2021. He joined InfanDx from a position as Managing Director of SphingoTec GmbH, a company developing and commercializing innovative diagnostic solutions in acute and critical care. Previously he held the position of CBO and Executive Board Member of the publicly listed Curetis Group (now OpGen Group), that focusses on molecular infectious disease diagnostics. He is a founding Managing Director of Ares Genetics GmbH, a digital diagnostics company and subsidiary of Curetis GmbH focusing on AI-powered molecular antibiotic susceptibility prediction. Prior to Curetis, Achim held a senior management position at Siemens Healthineers where he was responsible for Diagnostic and BioScience Technology & Innovation. Achim started his career in diagnostics at the cancer diagnostics company Epigenomics (Berlin, Germany), lastly as SVP Business & Strategy, that developed commercializes the first FDA-cleared liquid biopsy colorectal cancer screening test. Achim studied genetics, cell biology and biochemistry in Bonn, Germany, and Norwich, UK. He obtained his doctoral degree in Molecular Genetics from the University of Bonn in 2000.